NOXXON Presents Full Top-line Results From NOX-A12 Phase 1/2 GLORIA Trial in Glioblastoma at the 2022 ASCO Annual Meeting

Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the publication of the full top-line results from the NOX-A12 Phase 1/2 GLORIA trial in brain cancer (glioblastoma) in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, Illinois, US, from June 3 to June 7, 2022.

The poster presentation entitled “Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial” was presented by Dr. Frank A. Giordano and highlighted that:

• 90% of patients who received NOX-A12 and radiotherapy achieved tumor size reductions vs. 25% of patients in a matched reference cohort receiving standard of care.
• 40% of patients who received NOX-A12 and radiotherapy achieved partial response (defined as tumor size reduction of more than 50%) vs. 10% in a matched reference cohort receiving standard of care.
• In 30% of patients who received NOX-A12 and radiotherapy, one or more non-target lesions (smaller secondary lesions) completely disappeared.
• Infiltration of the tumor with activated, cytotoxic T-cells and M1-like macrophages was seen in both patients who had repeat surgery during NOX-A12 therapy, consistent with NOX-A12 and radiotherapy overcoming immune cell exclusion and making the tumors immunologically hotter.
• The combination of NOX-A12 and radiotherapy was safe and well tolerated, with no dose limiting toxicities and no treatment-related deaths. Only 4% of the adverse events of Grade 2 or more were deemed solely NOX-A12-related.

Aram Mangasarian, CEO of NOXXON, commented: "We are excited about these impressive results, which demonstrate the potential of our lead asset NOX-A12 in brain cancer and further substantiate our innovative approach of targeting the tumor microenvironment. We will continue to report on maturing data from the dose-escalation part of the study and are looking forward to interim read-outs from the ongoing expansion study exploring additional combination therapies, which will help us design our planned pivotal trial. Brain cancer is a very difficult to treat condition and these results bring us a step closer to offering improved treatment options and hope for patients."